/
NNNN
$13.55-$0.98 (-6.74%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$637.7M
44M shares
52-week range
$10.50 – $55.65
7% from low
Exchange
NASDAQ
CS
Borrow rate
173.35%
Hard to borrow
Price (6 mo)
Loading chart…
Change+$7.78
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $4.4M | $23.5M | $6.7M | $8.2M | $8.6M |
| Cost of revenue | $1.9M | $11.0M | $3.4M | $2.3M | $1.1M |
| Gross profit | $2.5M | $12.6M | $3.4M | $5.9M | $7.5M |
| Gross margin | 57.4% | 53.4% | 50.1% | 71.9% | 87.2% |
| R&D | $0 | $200.0K | $134.7K | $454.2K | $201.3K |
| Operating income | $2.5M | $10.2M | $2.0M | $2.0M | $5.8M |
| EBITDA | $2.5M | $10.0M | $2.3M | $2.6M | $5.8M |
| Net income | $2.5M | $10.0M | $2.3M | $2.4M | $6.4M |
| Net margin | 57.3% | 42.5% | 33.6% | 29.0% | 74.1% |
| EPS (diluted) | 0.03 | 0.07 | 0.01 | 0.06 | 0.16 |
Annual figures · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.85
Price
$13.55
Implied downside
-94%
Peer comparison
Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
www.anbio.com- Employees
- 27
- IPO / List date
- Feb 19, 2025
Held by traders on TradeandTell
No one on the platform currently holds NNNN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NNNN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NNNN yet.
